# US 2025/0367181 A1 · Centrally-Active Ghrelin Agonist and Medical Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367181 A1
- Document ID: US20250367181A1
- Status: Published application
- Kind: A1
- Application number: 19/300,850
- Filed: 2025-08-15
- Published: 2025-12-04
- Earliest claimed: 2018-03-22
- Assignees: Helsinn Healthcare SA
- Applicants: Helsinn Healthcare SA
- Inventors: Claudio Giuliano; Claudio Pietra; Silvina Garcia Rubio; Angelo Guainazzi; Marielle Martinez-Loi
- Web page: https://patentgrep.com/patent/US20250367181A1

## CPC

- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-l-(l,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.

## Claims

### Claim 1

The compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt, for use in treating and/or preventing a medical condition mediated by the ghrelin receptor in the central nervous system.

### Claim at position 2

2-14. (canceled)
